• PDF: Delivered by email within 12 to 24 hours of placing the order (Mon-Fri

Personalised Medicine Market in Europe

  • Publication Date:December 2010
  • Publisher:Frost & Sullivan
  • Product Type: Report
  • Pages:44

Personalised Medicine Market in Europe

The following 44 slides provide an analysis of key trends and issues of the personalised medicine industry globally with a key focus on issues pertaining to Europe. The study provides an overview of the key drivers, restraints and challenges that the personalised healthcare industry faces. It also provides a list of over 100 companies and their areas of focus in the personalised medicine ambit in addition to 30 deals.

This Frost & Sullivan research titled Personalised Medicine Market in Europe is an issue-based deliverable and examines market trends. It details over 30 pharma-diagnostic deals and lists over 100 companies present in this space and their areas of focus. The research also includes an in-depth discussion of key issues affecting the market.

Market Overview

Promise of Multiple Benefits Promotes Adoption of Personalised Medicine

Stating that current levels of double-digit growth are only the tip of the iceberg, Frost & Sullivan projects exponential growth for the European personalised medicine market. Defining the scope and nature of human biological variation allows the targeting of medical treatments towards those most likely to benefit from it. Such treatments may include drugs or cell therapies customised to a patient’s history, genes and immunology. In essence, the phenomenon of each human being unique creates immense opportunities for personalised medicine.

The European personalised medicine market is currently growing at double-digit growth rates, which is significant especially as it comes from an already high base. This growth rate is poised to increase as more European governments promote personalised healthcare, aiding its mainstream implementation. “The most important benefit of personalised medicine is that it improves the design, power and predictability of a clinical trial, which will then further aid in getting better outcomes in lesser time,” notes the analyst of this research. “Personalised medicine helps reduce subject recruiting time in clinical trials, improves drug response, and minimises adverse reactions.” It also reduces misdiagnoses. Personalised medicine enables faster diagnosis when applied as a companion diagnostic test along with a drug, thereby also aiding in developing better differentiated drug products. Promisingly, a number of public-private partnerships and high levels of technological advancements that support the discovery and development of new biomarkers will also spur market prospects.

Reimbursement Remains a Major Concern

The role of physicians is very critical in the promotion of companion diagnostic tests. These tests restrict physicians from prescribing a drug of their choice. “Often, they doubt the ability of a companion test to prescribe the drug compared to their knowledge and experience,” explains the analyst. “Therefore, removing this stigma and encouraging a new generation of physicians with a positive attitude towards theranostics will help to overcome this challenge.” The technical efficacy of theranostics, coupled with the lowering of associated research and development (R&D) costs will be key drivers in sustaining growth momentum in the market. However, pharmaceutical companies and diagnostic firms need to collaborate more closely with physicians during the theranostic development process, so that when the test is on the market, the endorsement of fellow physicians will aid in its greater adoption.

A key challenge remains reimbursement. This issue prevents physicians from prescribing companion diagnostic tests, as they are mostly out-of-pocket or only partly reimbursed. “Unless reimbursement issues are sorted out or these tests become affordable enough for full out of pocket payment, the companion diagnostic companies face a dead stand off,” cautions the analyst. “European governments are taking initiatives to solve these issues, which acts as a positive sign for personalised medicine companies.”

1. The Blockbuster Model

2. Introduction to Personalised Medicine

3. Clearing the Haze on Terminology

4. Role of Biomarkers in Personalised Medicine

5. Drug Development and Companion Diagnostic Development Pathways

6. Coordination of Therapeutics and Diagnostics Programs within an Integrated Pharmaceutical Company

7. Analysis of Stakeholders of Personalised Medicine

8. Benefits and Drivers of Personalised Medicine

9. Restraints and Challenges

10. Main Challenges to Personalised Medicine in EU

11. Analysis of Regulatory and Reimbursement issues of Personalised Medicine in Europe

12. Some Recent Personalised Medicine Initiatives and Policy News in Europe

13. Global List of Companies by Type of Focus

14. Companion Diagnostics Deals between 2000-2010, World

15. Key Observations from Pharma-Diagnostic Deals

16. Major Themes that have Emerged in Personalised Medicine

17. About Frost & Sullivan

List of Figures      
Personalised Medicine Market: Benefits to Stakeholders (World), 2010
Personalised Medicine Market: Comparison of Value of Drug Versus Companion Drug to Stakeholders (World), 2010
Personalised Medicine Market: Healthcare Delivery Models (Europe), 2010
Personalised Medicine Market: Examples of Reimbursement (Europe), 2010
Personalised Medicine Market: List of Companies by Type of Focus (World), 2010
Personalised Medicine Market: Companion Diagnostic Deals (World), 2000 –2010

Personalised Medicine Market: Value of Pharmaceutical Patent Expiries (World), 2001-2015
Personalised Medicine Market: Drug and Companion Diagnostic Development Pathway (World), 2010
Personalised Medicine Market: Factors for a Successful Biomarker Program (World), 2010
Personalised Medicine Market: Key Stakeholders (World), 2010
Personalised Medicine Market: Stakeholder Priorities, Pharmaceutical Company (World), 2010
Personalised Medicine Market: Stakeholder Priorities, Companion Diagnostic Manufacturer (World), 2010
Personalised Medicine Market: Stakeholder Priorities, Patient (World), 2010
Personalised Medicine Market: Stakeholder Priorities, Physician (World), 2010
Personalised Medicine Market: Stakeholder Priorities, Payer (World), 2010
Personalised Medicine Market: Key Benefits (World), 2010
Personalised Medicine Market: Key Drivers (World), 2010
Personalised Medicine Market: Key Restraints and Challenges (World), 2010
Personalised Medicine Market: Key Challenges (Europe), 2010
Personalised Medicine Market: Payment for Companion Diagnostic Tests (Europe), 2010
+44 20 8816 8548

Ask a question about Personalised Medicine Market in Europe

Enter the characters you see in the picture below